Annex B

National MAs authorised via MRP

- ***Solvent for cell associated poultry vaccines (MRP)***

MRP/DCP no. [1]	Member State EU/EEA [2]	National MA number	Marketing Authorisation Holder [3]	(Invented) name [4]	Active substance(s)	Strength(s) [5]	Pharmaceutical Form [6]
FR/V/0149/001	CZECH REPUBLIC	99/011-05-C	BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE SCS	Solvent for cell associated poultry vaccines	Not Applicable	Not Applicable	Solution for injection
	FRANCE	FR/V/3801690 7/2003					
	IRELAND	VPA 10857/69/1	BOEHRINGER INGELHEIM VETMEDICA GMBH. GERMANY				
	ITALY	103728010 103728022 103728034 103728046 103728059 103728061 103728073 103728085	BOEHRINGER INGELHEIM ANIMAL HEALTH ITALIA S.P.A				
	LITHUANIA	LT/2/05/1680/001-008	BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE SCS				
	NETHERLANDS	Reg. NL 10290	BOEHRINGER INGELHEIM ANIMAL HEALTH NETHERLANDS B.V.				
	SLOVAKIA	97/023-05-S	BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE SCS				
	UNITED KINGDOM (Northern Ireland)	Vm 08327/4219	BOEHRINGER INGELHEIM ANIMAL HEALTH UK LIMITED - UK				

[1] MRP/DCP no. of initial marketing authorisation
[2] List all the EEA Countries where the medicinal product(s) included in the worksharing are authorised, grouped by MRP/DCP no., with countries in alphabetical order (i.e. all medicinal products authorised in Austria, followed by all medicinal products authorised in Belgium, etc.)
[3] Name and address of the Marketing Authorisation Holder in the EEA Countries where the medicinal product is authorised
[4] As registered in the respective official language of the EEA Country (no strength or pharmaceutical form should be mentioned unless it is an integral part of the authorised (invented) name)
[5] It is possible to combine in the same row several strengths for the medicinal product in each Country. A separate row should however be used for each pharmaceutical form.
[6] Information in English - use current standard terms from the Ph. Eur.

- ***Cryomarex Rispens (MRP)***

MRP/DCP no.	Member State EU/EEA	National MA number	Marketing Authorisation Holder	(Invented) name	Active substance(s)	Strength(s)	Pharmaceutical Form
ES/V/0216/001/MR	BULGARIA	0022-2356	BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE SCS	CRYOMAREX RISPENS	Attenuated Marek's disease virus, Rispens strain	3.0 ≤ R ≤ 4.0 log_{10} PFU(*)/dose (*) PFU: Plaque Forming Units	Concentrate and solvent for suspension for injection
	CROATIA	UP/I-322-05/19-01/598					
	CYPRUS (GREEK)	CY00465V					
	CZECH REPUBLIC	97/051/14-C					
	GREECE	K-0207302					
	LATVIA	V/MRP/14/0044					
	LITHUANIA	LT/2/14/2243/001 LT/2/14/2243/002 LT/2/14/2243/003 LT/2/14/2243/004 LT/2/14/2243/005 LT/2/14/2243/006 LT/2/14/2243/007 LT/2/14/2243/008 LT/2/14/2243/009					
	ROMANIA	190214					
	SLOVENIA	MR/V/0494/001					
	SPAIN	2678ESP	BOEHRINGER INGELHEIM ANIMAL HEALTH ESPAÑA, S.A.U.				

Purely-national Mas

- ***Cryomarex Rispens***

Member State EU/EEA[7]	***National MA number***	***National variation no.[8]***	***Marketing Authorisation Holder[9]***	***(Invented) name[10]***	***Active substance(s)***	***Strength(s)[11]***	***Pharmaceutical Form[12]***
HUNGARY	2204/1/07 MgSzH ATI 2204/2/07 MgSzH ATI	Not applicable	BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE SCS	CRYOMAREX RISPENS VAKCINA A.U.V	Attenuated Marek's disease virus, Rispens strain	3.0 ≤ R ≤ 4.0 log10 PFU(*)/dose (*) PFU: Plaque Forming Units	Concentrate and solvent for suspension for injection
POLAND	478/98		BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE SCS	CRYOMAREX RISPENS			
PORTUGAL	473/92 DGV		BOEHRINGER INGELHEIM ANIMAL HEALTH PORTUGAL, UNIPESSOAL, LDA.				

[7] List all the EEA Countries where the medicinal product(s) included in the worksharing are authorised, in alphabetical order (i.e. all medicinal products authorised in Austria, followed by all medicinal products authorised in Belgium, etc.)
[8] If applicable
[9] Name and address of the Marketing Authorisation Holder in the EEA Countries where the medicinal product is authorised
[10] As registered in the respective official language of the EEA Country (no strength or pharmaceutical form should be mentioned unless it is an integral part of the authorised (invented) name)
[11] It is possible to combine in the same row several strengths for the medicinal product in each Country. A separate row should however be used for each pharmaceutical form.
[12] Information in English - use current standard terms from the Ph. Eur.

- ***Cryomarex HVT***

Member State EU/EEA	***National MA number***	***National variation no.***	***Marketing Authorisation Holder***	***(Invented) name***	***Active substance(s)***	***Strength(s)***	***Pharmaceutical Form***
POLAND	874/99	Not applicable	BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE SCS	CRYOMAREX HVT	HVT-FC 126 component	3.0 ≤ R ≤ 4.0 log10 PFU(*)/dose (*) PFU : Plaque Forming Units	Concentrate and solvent for suspension for injection
PORTUGAL	377/90 DGV		BOEHRINGER INGELHEIM ANIMAL HEALTH PORTUGAL, UNIPESSOAL, LDA.				
SPAIN	2469 ESP		BOEHRINGER INGELHEIM ANIMAL HEALTH ESPAÑA, S.A.U.				

- ***Cryomarex Rispens+HVT***

Member State EU/EEA	***National MA number***	***National variation no.***	***Marketing Authorisation Holder***	***(Invented) name***	***Active substance(s)***	***Strength(s)***	***Pharmaceutical Form***
BULGARIA	0022-1468	Not applicable	BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE SCS	CRYOMAREX RISPENS+HVT	Attenuated Marek's disease virus, Rispens strain	3.0 ≤ R ≤ 4.0 log10 PFU(*)/dose	Concentrate and solvent for suspension for injection
HUNGARY	2205/1/07 MgSzHATI 2205/2/07 MgSzHATI			CRYOMAREX RISPENS+HVT VAKCINA A.U.V			
POLAND	477/98			CRYOMAREX RISPENS+HVT	Attenuated Marek's disease virus, HVT-FC 126 strain	3.0 ≤ R ≤ 4.0 log10 PFU(*)/dose (*) PFU: Plaque Forming Units	